Akebia Competitors

AKBA Stock  USD 2.06  0.01  0.49%   
Akebia Ther competes with Protalix Biotherapeutics, Cidara Therapeutics, X4 Pharmaceuticals, Seres Therapeutics, and Ocean Biomedical; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Akebia Ther competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Akebia Ther to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Akebia Ther Correlation with its peers.
For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Akebia Ther competition on your existing holdings.
  
The current year's Return On Equity is expected to grow to 1.78, whereas Return On Tangible Assets are forecasted to decline to (0.37). At present, Akebia Ther's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 182 M, whereas Other Current Assets are forecasted to decline to about 12.6 M.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.102.075.84
Details
Intrinsic
Valuation
LowRealHigh
0.122.476.24
Details
3 Analysts
Consensus
LowTargetHigh
3.533.884.31
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.07-0.07-0.07
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Akebia Ther. Your research has to be compared to or analyzed against Akebia Ther's peers to derive any actionable benefits. When done correctly, Akebia Ther's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Akebia Ther.

Akebia Ther Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Akebia Ther and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Akebia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Akebia Ther does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CDTXPLX
AVROPLX
ENVBOCEA
AVROCDTX
OCEAXFOR
ENVBXFOR
  
High negative correlations   
OCEAPLX
ENVBPLX
OCEAAVRO
OCEACDTX
XFORPLX
ENVBCDTX

Risk-Adjusted Indicators

There is a big difference between Akebia Stock performing well and Akebia Ther Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Akebia Ther's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PLX  3.12  1.17  0.28 (1.38) 2.39 
 10.00 
 20.38 
CDTX  2.85  0.70  0.21  1.95  2.50 
 7.38 
 25.29 
XFOR  5.02 (0.47) 0.00 (0.22) 0.00 
 8.82 
 62.35 
MCRB  4.99  0.45  0.06  1.50  5.62 
 10.84 
 28.84 
AVRO  1.77  0.16  0.01 (0.96) 1.89 
 4.11 
 14.20 
CWBR  7.34  2.41  0.33  6.02  5.34 
 5.73 
 250.97 
OCEA  3.47 (0.31) 0.00 (0.83) 0.00 
 7.46 
 28.33 
ENVB  3.24 (0.58) 0.00 (3.98) 0.00 
 6.25 
 28.33 
ELEV  3.46 (0.37) 0.00 (0.05) 0.00 
 5.77 
 22.21 
HEPA  3.78 (0.37) 0.00 (0.09) 0.00 
 8.06 
 33.54 

Cross Equities Net Income Analysis

Compare Akebia Ther and related stocks such as Protalix Biotherapeutics, Cidara Therapeutics, and X4 Pharmaceuticals Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
PLX131.7 K(36.5 M)(11.6 M)(27.8 M)(29.9 M)58 M(29.4 M)(85.3 M)(26.5 M)(26.2 M)(14.9 M)(34 M)(14.9 M)8.3 M8.7 M
CDTX(1.3 M)(1.3 M)(1.3 M)(1.3 M)(11.9 M)(32.2 M)(48.2 M)(55.7 M)(59 M)(40.1 M)(72.4 M)(43.9 M)(29.8 M)(22.9 M)(24.1 M)
XFOR(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(13.2 M)(23 M)(33.9 M)(43 M)(56.6 M)(62.1 M)(88.7 M)(93.9 M)(101.2 M)(96.1 M)
MCRB(3.1 M)(3.1 M)(3.1 M)(6.1 M)(16.7 M)(54.8 M)(91.6 M)(89.4 M)(98.9 M)(64.2 M)(86.5 M)(61.5 M)(253.8 M)(113.7 M)(119.4 M)
OCEA(232 K)(232 K)(232 K)(232 K)(232 K)(232 K)(232 K)(232 K)(232 K)(232 K)(1.7 M)(62.3 M)565.5 K508.9 K534.4 K
ENVB(1.2 M)(33.4 K)(24.6 K)(161)(33.6 K)(1.9 M)(2.8 M)(9.1 M)(16.9 M)(5.6 M)(6.4 M)(49 M)(18.5 M)(17.3 K)(18.2 K)
ELEV(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(5.9 M)(17.3 M)(32 M)(95.1 M)(45.7 M)(48 M)
HEPA(843 K)(843 K)(843 K)(5.3 M)(5.3 M)(14.3 M)(17 M)(14.9 M)(9.4 M)(7 M)(20.4 M)(32.7 M)(42.2 M)(48.9 M)(46.5 M)

Akebia Ther and related stocks such as Protalix Biotherapeutics, Cidara Therapeutics, and X4 Pharmaceuticals Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Akebia Ther financial statement analysis. It represents the amount of money remaining after all of Akebia Ther operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Akebia Ther Competitive Analysis

The better you understand Akebia Ther competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Akebia Ther's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Akebia Ther's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AKBA PLX CDTX XFOR MCRB AVRO CWBR OCEA ENVB ELEV
 0.49 
 2.06 
Akebia
 1.78 
 1.72 
Protalix
 0.05 
 20.21 
Cidara
 11.43 
 0.39 
XFOR
 6.52 
 0.98 
Seres
 2.78 
 1.40 
AVROBIO
 2.29 
 2.99 
CohBar
 1.41 
 0.70 
Ocean
 3.13 
 0.33 
Enveric
 3.23 
 0.64 
Elevation
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Akebia Ther Competition Performance Charts

Five steps to successful analysis of Akebia Ther Competition

Akebia Ther's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Akebia Ther in relation to its competition. Akebia Ther's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Akebia Ther in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Akebia Ther's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Akebia Ther, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Akebia Ther position

In addition to having Akebia Ther in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alternative Currency ETFs Thematic Idea Now

Alternative Currency ETFs
Alternative Currency ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:
Check out Akebia Ther Correlation with its peers.
For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.834
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.09)
Return On Equity
(5.53)
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.